Abbreviations used: AML -acute myeloid leukemia; BACH1 helicase -BRCA1 interacting protein C-terminal helicase 1 [Homo sapiens]; BRCA1 -breast cancer susceptibility gene 1; BRCT -BRCA C-terminus; LOH -loss of heterozygosity; RecA -RecA protein (Recombinase A); MRE11 -meiotic recombination 11 homologue A; NBS1 -Nijmegen breakage syndrome 1 (nibrin, NBN); p53 -tumor protein 53; RAD50 -RAD50 homologue (Saccharomyces cerevisiae) [ Abstract: Breast cancer is the most prevalent cancer type in women. Accumulating evidence indicates that the fidelity of double-strand break repair in response to DNA damage is an important step in mammary neoplasias. The RAD51 and BRCA1 proteins are involved in the repair of double-strand DNA breaks by homologous recombination. In this study, we evaluated loss of heterozygosity (LOH) in the RAD51 and BRCA1 regions, and their association with breast cancer. The polymorphic markers D15S118, D15S214 and D15S1006 were the focus for RAD51, and D17S855 and D17S1323 for BRCA1. Genomic deletion detected by allelic loss varied according to the regions tested, and ranged from 29 to 46% of informative cases for the RAD51 region and from 38 to 42% of informative cases for the BRCA1 region. 25% of breast cancer cases displayed LOH for at least one studied marker in the RAD51 region exclusively. On the other hand, 31% of breast cancer cases manifested LOH for at least one microsatellite marker concomitantly in the RAD51 and BRCA1 regions. LOH in the RAD51 region, CELLULAR & MOLECULAR BIOLOGY LETTERS 193 similarly as in the BRCA1 region, appeared to correlate with steroid receptor status. The obtained results indicate that alteration in the RAD51 region may contribute to the disturbances of DNA repair involving RAD51 and BRCA1 and thus enhance the risk of breast cancer development.
INTRODUCTION
Breast cancer occurs in both hereditary and sporadic forms, and is a great problem in public health all over the world. Although mutations in the BRCA1 gene seem to be the most essential for familial and sporadic breast cancer, it has become clear that breast cancer is a complex phenomenon in which multiple genes may play a role. A wide variety of cellular pathway alterations may confer and increase the risk of breast cancer. Among them, the DNA damage response is of great importance. DNA repair is critical for maintaining genome integrity. The BRCA1 gene product was found to be involved in the repair of doublestrand DNA breaks by homologous recombination, particularly through the mechanism involving RAD51. Thus, RAD51 may contribute to breast cancer by maintaining genomic integrity and/or modifying the penetrance of BRCA1 mutations [1] [2] [3] [4] . The RAD51 gene located on chromosome 15q15.1 consists of 10 exons and 9 introns, and spans at least 30 kb [5] . The human RAD51 gene encodes a 339-amino acid protein with a molecular weight of 37 kDa, a homologue of the RecA protein of Escherichia coli and Rad51 of Saccharomyces cerevisiae, and is involved in both meiotic and mitotic recombination. The RAD51 protein seems to be essential for maintaining genomic stability, and it plays a central role in the homology-dependent recombinational repair of DNA double-strand breaks [6, 7] . RAD51 binds to single and double-stranded DNA, exhibits DNAdependent ATPase activity to form nucleoprotein filaments, and mediates homologous pairing and strand exchange between DNA duplexes [8] [9] [10] . RAD51 is expressed in proliferating cells with the highest level in the S or S/G 2 phase of the cell cycle [11] [12] [13] . Specific interaction between RAD51 and such proteins as BRCA1, BRCA2, p53 and RAD52 has been described [14] [15] [16] [17] [18] . BRCA1 was shown to bind with RAD51 and co-localize with RAD51 in mitotic and meiotic cells [19, 20] . BRCA1 is a tumor suppressor gene located on chromosome 17q21, and it spans 100 kb of genomic DNA [21] . The BRCA1 gene encodes a nuclear phosphoprotein of 220 kDa consisting of 1863 amino acids, which has a highly conserved amino terminal RING finger domain and a C-terminal domain (BRCT) characteristic for many transcription factors [22] [23] [24] . Two BRCT motifs have been identified in BRCA1 and in several other proteins involved in cellcycle control regulation in response to DNA damage [25, 26] . BRCA1 was found to be involved in several important cellular functions, including DNA [20, [31] [32] [33] [34] [35] [36] . The accumulated data suggests that genetic instability of BRCA1 is associated with an increased relative risk of breast cancer [37, 38] . The aim of this study was to evaluate if RAD51 chromosomal region alteration contributes to breast cancer. We evaluated loss of heterozygosity (LOH) in the RAD51 and BRCA1 regions, and their association with breast cancer. The polymorphic markers D15S118, D15S214 and D15S1006 were the focus for RAD51, and D17S855 and D17S1323 for BRCA1. The relationship of LOH with clinicopathological parameters was examined to reveal the potential role of the studied genes in breast cancer development.
MATERIALS AND METHODS

Patients
Thirty six paraffin-embedded tissue samples from patients with primary breast cancer and matched blood samples were obtained at the Department of Clinical Pathomorphology of the Polish Mother's Memorial Hospital Research Institute, Łódź, Poland. The mean age of the patients was 57, ranging from 32 to 79. Fourteen were 50 years old or younger, and 22 were over the age of 50. All the tumor specimens underwent clinicohistopathological evaluations. All were classified as ductal carcinoma. The series included 35 cases at stage II and 1 at stage III, according to the modified Bloom-Richardson criteria. Twenty seven cases were positive and 9 negative with respect to estrogen receptors, 17 were positive and 19 negative with respect to progesterone receptors, and 20 cases were negative and 16 positive with respect to lymph node status.
DNA isolation
DNA was isolated from peripheral blood and tissue samples following the standard phenol extraction procedure. The paraffin-embedded tissue samples were extracted with xylene to remove the paraffin [39, 40] .
PCR conditions and primers
The specimens were investigated for genetic alterations at the two genetic regions using 5 microsatellite markers. For RAD51, we focused on the polymorphic microsatellite markers D15S118, D15S214 and D15S1006, oriented along the chromosomal region 15q14-q21. The localization of the studied markers is as follows: D15S118-12996900-12997100 bp, D15S214-17166170-17166435 bp, D15S1006-24439646-24439859 bp. The RAD51 gene is located between 17791587 and 17792320 bp (NCBI, Gene Map, Celera). The marker D15S118 is at the centromeric position, D15S214 at the middle, and D15S1006 at the telomeric, relative to the RAD51 gene. For BRCA1, we focused on the intragenic microsatellite markers D17S855 and D17S1323 (intron 20 and 12) (J. Weissenbach, Genethon, Whitehead Institute Center for Genome Research). The sequences of primers used for PCR are shown in Tab. 1. The sequences for all the primers are listed in the Human Genome Database (www.gdb.org). The primers were synthesized and labeled fluorescently by Applied Biosystems (USA). Polymerase chain reaction (PCR) was carried out in a 7.5 µl reaction volume containing 50 ng of genomic DNA, 0.3 units of AmpliTaq Gold TM DNA polymerase (5 U/µl), 1 x GeneAmp ® PCR Gold Buffer (10 x concentration), 1 mM GeneAmp dNTP Mix (10 mM), 2.5 mM magnesium chloride (25 mM) and 5 pmol of either forward or reverse primer end-labeled with the dye phosphoramidite 6-FAM or TET. A 30-cycle amplification (denaturation, annealing and extension) was done in a GeneAmp 2400 thermal cycler (PerkinElmer, USA). The PCR cycles for each marker are presented in Tab. 1. automatically. Allele sizing was determined with GeneScan version 3.1.2 and Genotyper version 2.5 softwares (Applied Biosystems, USA), and also calculated as described by Cawkwell et al. [41] , with reciprocal correction as required. LOH was defined as ≥ 50% reduction (allelic ratio ≤ 0.5) in either allele in the tumor compared with the normal counterpart.
Statistical analysis
All the comparisons between LOH and clinicopathological parameters were performed using the Fisher test. P-values of 0.05 or less were considered statistically significant. The statistical analysis was performed using the Statistica package, version 5.
RESULTS
The LOH analysis of the RAD51 and BRCA1 regions was performed on the microsatellite markers D15S118, D15S214 and D15S1006 for the former, and D17S855 and D17S1323 for the latter, using DNA isolated from the tumor and matched peripheral blood of 36 breast cancer patients. The LOH study detected the loss of a single copy of the two alleles. Those with detectable heterozygous alleles are defined as informative cases. As shown in Tab. 2, genomic deletion detected by allelic loss varied according to the region tested, and ranged from 29% (6/21) to 46% (12/26) of informative cases for the RAD51 region and from 38% (8/21) to 42% (11/26) of informative cases for the BRCA1 region. A high incidence of LOH (41%) was observed for the highly informative microsatellite marker D15S214, which is located near the RAD51 locus. 25% (9/36) of the studied breast cancer cases displayed LOH for at least one microsatellite marker in the RAD51 region. 31% (11/36) of breast cancer cases manifested LOH for at least one microsatellite marker concomitantly in the RAD51 and BRCA1 regions. The LOH in the RAD51 and BRCA1 regions and clinicopathological parameters were compared using the Fisher test. The LOH at D15S118 and D15S214 was found to be significantly more frequent in the estrogen-receptor positive than in the estrogen-receptor negative patients (P = 0.03 and P = 0.02). There was a trend towards statistical significance in the frequency of LOH at D15S118, D15S214 and D15S1006 with positive progesterone receptor status (P = 0.01, P = 0.02 and P = 0.01, respectively) (Tab. 3). LOH at D17S855 and D17S1323 also occurred frequently in tumors with positive progesterone receptor (P = 0.03, P = 0.04) and negative nodal status (P = 0.04) compared to those with negative progesterone receptor and positive nodal status. Furthermore, the incidence of LOH at D17S855 was also associated with positive estrogen receptor status (P = 0.04) (Tab. 4). These results seem to suggest that genetic instability in the RAD51 and BRCA1 regions occurs early in mammary carcinogenesis.
DISCUSSION
Genomic instability is one of the main features of cancer cells. It is expressed by the accumulation of chromosomal aberrations, mutations, loss of heterozygosity and microsatellite instability. LOH is observed in the early and late stages of the neoplastic transformation process [42] . Because of the high level of specificity, LOH has recently become invaluable as a marker for the diagnosis and prognosis of cancer [43] . The repair of chromosomal double-strand breaks is essential to maintain genomic integrity, yet the various repair pathways are variably mutagenic. RAD51 and BRCA1 proteins are involved in double-strand break repair by homologous recombination [44, 45] . Single nucleotide polymorphisms have been identified in the 5' untranslated region of RAD51, namely 5'UTRg135c and 5'UTRg172t [46] . RAD51-135c itself has not been demonstrated to elevate the risk of breast cancer [47] [48] [49] [50] . It is not clear whether BRCA1 mutation carriers, which also carried the RAD51-135c variant, had a higher susceptibility of developing breast cancer compared with BRCA1 mutation carriers without this single nucleotide polymorphism. Wang et al. [46] suggested that single nucleotide polymorphisms in the RAD51 5' untranslated region might be associated with an increased risk of breast cancer among BRCA1 mutation carriers. A matched case study of Polish women showed instead that RAD51-135c is associated with a decreased risk of breast cancer in women who carry the BRCA1 mutation 5382insC [51] . No or a low association was detected between epithelial ovarian cancer risk and RAD51 g135c and RAD51 g172t [3, 46] . On the other hand, both de novo and therapy-related acute myeloid leukemia (AML and t-AML) have been found to be associated with RAD51-135c polymorphism [52] . Schmutte et al. [5] did not find any mutations in the RAD51 coding sequence or intron/exon boundaries, or hypermethylation in the promoter region in breast cancer and metastatic brain tumors. A sequence analysis of the coding region of the RAD51 cDNA demonstrated no point mutations or microdeletions in the parathyroid cancer [53]. Kato et al. [54] found a missense mutation in two patients with familial breast cancer: a G-to-A transition converting codon 150 from CGG (Arg) to CAG (Gln). Both patients had bilateral breast cancer, one with synchronous bilateral breast cancer and the other with synchronous bilateral multiple breast cancer.
Loss of heterozygosity in the genomic region 15q14-q21, containing RAD51, has been reported in 32-70% of breast cancer cases [55] [56] [57] , 56% of lung cancer [55] , 67% of colorectal cancer [55] , 46-54% of malignant mesothelioma [58, 59] , and 39% of bladder transitional cell carcinoma [60] . LOH at 17q21 has been revealed in about 30-60% of breast [61, 62] , ovarian [63] and colorectal [64] cancer cases. Gonzalez et al. [56] observed LOH at the RAD51 and BRCA1 regions for at least one marker, respectively in 32% and 49% of breast cancers. In our study, 25% of breast cancer cases displayed LOH for at least one microsatellite marker in the RAD51 region exclusively. On the other hand, 31% of cases manifested LOH for at least one microsatellite marker both in the RAD51 and BRCA1 regions. The obtained results suggest that RAD51 alterations may play a critical role in genomic instability due to the lack of efficiency of DNA repair involving the RAD51 and BRCA1 genes. Recent studies indicated that allelic loss in the aforementioned regions might be associated with clinicopathological features of breast cancer. Statistically significant differences between breast tumors with and without LOH in the RAD51 and BRCA1 regions have been found with respect to estrogen receptor content, progesterone receptor content, higher grade, and stage [56, 65, 66] . Johnson et al. [62] detected allelic loss of BRCA1 with higher frequency in women under 36 compared to postmenopausal patients. However, this difference was not statistically significant. On the contrary, Santos et al. [67] observed no correlation when LOH frequency in the BRCA1 region was compared with tumor size or grade, or the presence of axillary lymph node metastasis. In our study, when LOH in the RAD51 and BRCA1 regions was correlated with the clinicopathological parameters of breast cancer, we noticed statistically significant differences mainly between tumors with LOH and estrogen and progesterone receptor status. These results indicate that further studies are needed to establish more specific association of LOH in the RAD51 and BRCA1 regions with clinicopathological parameters in breast cancer.
